Vanda Pharmaceuticals

Entity type image
Type: Company
Name: Vanda Pharmaceuticals
First reported 11 hours ago - Updated 11 hours ago - 3 reports

Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland

VANDA PHARMACEUTICALS INC Symbol U : VNDA Recent Sedar Documents Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland ... [Published Stockwatch - 11 hours ago]
First reported May 20 2013 - Updated May 20 2013 - 1 reports
Morgans Hotel Group Co
Morgans Hotel Group Co

Stocks in Focus: Vanda Pharmaceuticals Inc, National Bank of Greece (ADR), ViaSat Inc, Morgans Hotel Group Co

Austin, TX -- ( SBWIRE ) -- 05/20/2013 -- Jackpotpennystocks.com , an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:-Vanda Pharmaceuticals ... [Published SBWire - May 20 2013]
First reported May 20 2013 - Updated May 20 2013 - 1 reports
SolarCity
SolarCity

Free Research Reports on MERU, RSOL, SCTY and VNDA Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News CircuitNEW YORK, NY--(Marketwired - May 20, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely ... [Published Market Wire - May 20 2013]
First reported May 17 2013 - Updated May 17 2013 - 1 reports

Vanda Pharmaceuticals price target raised to $17 from $11 at Lazard Capital Theflyonthewall.com

Lazard Capital raised its price target for Vanda Pharmaceuticals shares citing positive feedback on the company's sleep disorder drug tasimelteon. The firm keeps a Buy rating on the stock. ... [Published Yahoo! Finance - May 17 2013]
First reported May 17 2013 - Updated May 17 2013 - 1 reports

Recent 52-Week High Exceeded in Shares of Vanda Pharmaceuticals (VNDA)

(Financial News NetwFork O) Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded at a new 52-week high today of $7.23. So far today approximately 2.8 million shares have been exchanged, as compared to an average 30-day volume of 294,000 shares. Van ... [Published Individual.com - May 17 2013]
First reported May 17 2013 - Updated May 17 2013 - 1 reports
Triple-S Management Corp
Triple-S Management Corp

Healthcare Review: Vanda Pharmaceuticals, Triple-S Management, Stemline Therapeutics, VIVUS, Celsion Corporation

U.S. stocks advanced on Friday, with the S&P 500 erasing declines in the previous session, putting the index on track for its fourth straight weekly advance as data helped support recent momentum. The benchmark S&P 500 index fell 0.5 percent on Thursday, ... [Published BioMedReports - May 17 2013]
First reported May 17 2013 - Updated May 17 2013 - 1 reports
Real Goods Solar Inc
Real Goods Solar Inc

Top Percentage Gainers: SolarCity Corp, Vanda Pharmaceuticals Inc., Marketo Inc, Real Goods Solar, Inc.

Huntington Beach, CA -- (SBWIRE) -- 05/17/2013 -- PSPicks.com provides its subscribers with a free newsletter that reports up to the minute information and exclusive charts on cheap, undervalued, hidden, and undiscovered stocks traded on the NASDAQ, ... [Published SBWire - May 17 2013]
First reported May 17 2013 - Updated May 17 2013 - 1 reports

Top Performing Industries For May 17, 2013

At 10:17 am, the Dow surged 0.36% to 15,288.10, the broader Standard & Poor's 500 index moved up 0.51% to 1,658.94 and the NASDAQ composite index rose 0.52% to 3,483.38.The industries that are performing well in the market today are:Medical Practitioners: ... [Published Benzinga.com - May 17 2013]
First reported May 14 2013 - Updated May 14 2013 - 1 reports

Vanda Pharmaceuticals: The Winning...

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded today at $5.45, breaking its 52-week high. Approximately 439,000 shares have changed hands today, as compared to an average 30-day volume of 247,000 shares.Potential upside of 57.1% exists for Vanda ... [Published Financial News Network online - May 14 2013]
First reported May 13 2013 - Updated May 13 2013 - 1 reports

Vanda Pharmaceuticals Trading Higher on...

Vanda Pharmaceuticals's stock is up 1.6% to $5.14 on heavy trading volume. Today's volume of 371,000 shares tops the average 30-day volume of 232,000 shares. Spikes in volume can validate a breakout or signify a potential turning point. Vanda Pharmaceuticals ... [Published Financial News Network online - May 13 2013]
First reported May 09 2013 - Updated May 09 2013 - 4 reports

Vanda Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript

10:00 AM ETOperatorGood day, ladies and gentlemen, and welcome to the First Quarter 2013 Vanda Pharmaceuticals Earnings Conference Call. My name is Lisa, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is ... [Published Seeking Alpha - May 09 2013]
First reported May 09 2013 - Updated May 09 2013 - 1 reports

VANDA PHARMACEUTICALS INC. : Vanda Pharmaceuticals Reports First Quarter 2013 Results

(4-traders.com)WASHINGTON, May 9, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today ... [Published 4 Traders - May 09 2013]

Quotes

"We are deeply honored to receive this recognition from the Tech Council of Maryland"
Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland [Published ADVFN UK - 11 hours ago]
...are deeply honored to receive this recognition from the Tech Council of Maryland," said Mihael H Polymeropoulos, M D , President and CEO of Vanda. "We are privileged to work in a region that is supportive of our efforts to develop new treatments designed to improve the lives of others." In selecting Vanda for this award, the TCM recognized Vanda's commitment to address patient needs and the company's work to develop tasimelteon, a circadian...
Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland [Published TickerTech.com - 11 hours ago]
...87 percent on volume of 8.95 million shares traded Friday to close at $4.03 a share. The company recently launched their "PowerOn" kit. "PowerOn makes converting to solar energy easier than ever with pre-packaged, professionally designed residential systems starting at less than $6,000" said Kam Mofid, CEO Real Goods Solar
Free Research Reports on MERU, RSOL, SCTY and VNDA Issued by the Paragon Report [Published Market Wire - May 20 2013]
...First quarter 2013 and "12 revenues each included $1.5 million in Fanapt royalties received from Novartis. During each period, Vanda recognized the 10% royalty on Novartis" net sales of Fanapt. Total operating expenses for the first quarter of 2013 were $12.3 million compared to $16...
Vanda Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript [Published Seeking Alpha - May 09 2013]

More Content

All (99) | News (68) | Reports (5) | Blogs (11) | Audio/Video (0) | Fact Sheets (0) | Press Releases (15)
sort by: Date | Relevance
Vanda Pharmaceuticals Named the 2013 Life Scien... [Published Stockwatch - 11 hours ago]
Vanda Pharmaceuticals Named the 2013 Life Scien... [Published ADVFN UK - 11 hours ago]
Vanda Pharmaceuticals Named the 2013 Life Scien... [Published TickerTech.com - 11 hours ago]
Vanda Pharmaceuticals Named the 2013 Life Scien... [Published PR Newswire: General Business - 11 hours ago]
Research Reports on Hot Biotech Stocks: PPHM, A... [Published SBWire - May 20 2013]
Stocks in Focus: Vanda Pharmaceuticals Inc, Nat... [Published SBWire - May 20 2013]
Free Research Reports on MERU, RSOL, SCTY and V... [Published Market Wire - May 20 2013]
Top Heated Stocks (SCTY, VNDA, COCO, XIDE) [Published SBWire - May 17 2013]
Vanda Pharmaceuticals price target raised to $1... [Published Yahoo! Finance - May 17 2013]
Recent 52-Week High Exceeded in Shares of Vanda... [Published Individual.com - May 17 2013]
Unusual 11 Mid-Day Movers 05/17: (RSOL) (SCTY) ... [Published Street Insider - May 17 2013]
Healthcare Review: Vanda Pharmaceuticals, Tripl... [Published BioMedReports - May 17 2013]
Top Percentage Gainers: SolarCity Corp, Vanda P... [Published SBWire - May 17 2013]
Top Performing Industries For May 17, 2013 [Published Benzinga.com - May 17 2013]
Reporters Notebook: A familiar top tech exec [Published Gazette.net - May 17 2013]
Vanda Pharmaceuticals: The Winning... [Published Financial News Network online - May 14 2013]
Vanda Pharmaceuticals: The Winning Streak Conti... [Published Individual.com - May 13 2013]
Stocks Hitting 52-Week Highs [Published TD Ameritrade - May 13 2013]
Vanda Pharmaceuticals Trading Higher on... [Published Financial News Network online - May 13 2013]
5 Healthcare Stock Earnings Snapshots [Published Wall St. Cheat Sheet - May 12 2013]
Vanda Pharmaceuticals Price Target Increased to... [Published American Banking News - May 10 2013]
Shares of Vanda Pharmaceuticals Has Risen Above... [Published Comtex SmarTrend - May 10 2013]
Actavis Confirms District Court Ruling In Gener... [Published BioMedReports - May 10 2013]
Vanda Pharmaceuticals Shares Up 23.7% Since Sma... [Published Comtex SmarTrend - May 10 2013]
U.S./Canada daily earnings hits & misses May 9 ... [Published Globe and Mail - May 09 2013]
Vanda Pharmaceuticals Management Discusses Q1 2... [Published Seeking Alpha - May 09 2013]
Shares of Vanda Pharmaceuticals Rise to... [Published Financial News Network online - May 09 2013]
Shares of Vanda Pharmaceuticals Rise to a New 5... [Published Individual.com - May 09 2013]
Vanda Pharmaceuticals, Inc. (VNDA) Reports Firs... [Published BioSpace - May 09 2013]
Vanda Pharmaceuticals Earnings: Here’s Why Shar... [Published Wall St. Cheat Sheet - May 09 2013]
1 2 3 4
In Focus
  •  
Jim Kelly, Mihael H Polymeropoulos, Dannel Malloy, [more]
  •  
Lazard Capital Markets, Novartis AG, Supernus Pharmaceuticals Inc, [more]
  •  
Tech Council of Maryland, European Medicines Agency, University of Milan, [more]
  •  
Central Nervous System, Stocks, 8-k, [more]
  •  
Fanapt, Xignite Financials, S&P 500, [more]
  •  
Boston (Massachusetts, United States), Austin, New York City, [more]
  •  
Italy, United States, Israel, [more]
  •  
Diseases, Medication, Research & Development, [more]
  •  
IT, Real Estate, Banking & Financial Services, [more]
SEC Filings, Financial News Network online, Individual.com, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
5 Healthcare Stock Earnings Snapshots [Published Wall St. Cheat Sheet - May 12 2013]
Sunesis Pharmaceuticals Inc. ( NASDAQ:SNSS ) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. Adjusted Earnings Per Share increased to $-0.23 in the quarter versus EPS of $-0.30 in the year-earlier quarter. Revenue ...
Vanda Pharmaceuticals Earnings: Here’s Why Shar... [Published Wall St. Cheat Sheet - May 09 2013]
Vanda Pharmaceuticals, Inc. ( NASDAQ:VNDA ) had a loss and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are ...
News and press releases: Vanda Pharmaceuticals ... [Published Patient safety, news and press releases: human ... - Mar 14 2013]
The European Medicines Agency has been formally notified by Vanda Pharmaceuticals Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Fanaptum (iloperidone) intended to be used for the treatment of ...
Former FDA Chemist Is Debarred For Insider Trading [Published Pharmalot - Mar 07 2013]
Two years ago, FDA chemist Cheng Yi Liang was arrested for using confidential information about upcoming announcements of 27 different approval decisions involving 19 publicly traded companies over a five-year period. In the process, he generated more ...
4 Healthcare Stock Stories for Thursday Wellness [Published Wall St. Cheat Sheet - Jan 31 2013]
Johnson & Johnson ( NYSE:JNJ ): Current price $74.08 The European Commission has sent  antitrust objections  to Novartis ( NYSE:NVS ) and Johnson & Johnson in regards to a pay-for-delay arrangement that might have deterred sales of generic versions ...
1 2 3

Press Releases

sort by: Date | Relevance
Vanda Pharmaceuticals Named the 2013 Life Scien... [Published PR Newswire: General Business - 11 hours ago]
Vanda Pharmaceuticals Reports First Quarter 201... [Published Financial Services - May 09 2013]
Vanda Pharmaceuticals to Announce First Quarter... [Published PR Newswire: Health - Apr 18 2013]
Vanda Pharmaceuticals Appoints Dr. Paolo Barold... [Published PR Newswire: General Business - Apr 18 2013]
Vanda Pharmaceuticals to Present at the BioCent... [Published PR Newswire: Health - Apr 05 2013]
1 2 3
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.